Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06518941 · ClinicalTrials.gov registry record · Phase 2
An Open Trial of a Novel Pharmacotherapy for Habit Modification in Anorexia Nervosa
A Phase 2 study, sponsored by New York State Psychiatric Institute.
- Not yet
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
NCT06518941 is a Phase 2 study that has not yet begun recruiting, run by New York State Psychiatric Institute. The registered enrollment target is 10 participants.
The verdict
NCT06518941, a Phase 2 study, has not yet begun recruiting, sponsored by New York State Psychiatric Institute.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
Study Summary
The purpose of this study is to test the feasibility and tolerability of donepezil in a small group of patients with anorexia nervosa (AN). Study participants will be receiving care at the New York State Psychiatric Institute Eating Disorders Unit. Study medication will be increased from 1 mg per day to a maximum of 5 mg per day for up to 8 weeks. Participants will be closely monitored for side effects by a research psychiatrist every week, in addition to the regular clinical monitoring they receive during inpatient treatment. The study will also include assessments of habit strength to measure any changes in maladaptive eating habits over the course of the treatment.
Interventions
- DRUG Donepezil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2026-06 |
| Est. Completion | 2027-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06518941
The ClinicalTrials.gov registry entry for NCT06518941 describes a study currently listed as not yet recruiting, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is New York State Psychiatric Institute, which has 364 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Donepezil is the first listed.
NCT06518941 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06518941 about?
NCT06518941 is a clinical study titled "An Open Trial of a Novel Pharmacotherapy for Habit Modification in Anorexia Nervosa". The purpose of this study is to test the feasibility and tolerability of donepezil in a small group of patients with anorexia nervosa (AN). Study participants will be receiving care at the New York State Psychiatric Institute Eating Disorders Unit. Study medication will be increased from 1 mg per da...
What is the current status of trial NCT06518941?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2026-06. Estimated completion is 2027-12.
What interventions are being tested in trial NCT06518941?
The interventions under investigation include: Donepezil (DRUG).
Who is sponsoring clinical trial NCT06518941?
This trial is sponsored by New York State Psychiatric Institute, which has 364 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.